Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
MonumenTAL-1
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
Iberdomide vs. Observation Post Ide-Cel CAR-T
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
- CELMoD
- Maintenance
- Randomization
- Phase 2
Accepting patients
MRD-Guided Elranatamab Maintenance Therapy
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Bispecific Antibody
- BCMA
- CD3
- Maintenance
- Phase 2
Accepting patients
Sonrotoclax (BGB-11417)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
Investigational Cord Blood Units
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Cord Blood
- Phase 2
Accepting patients
Cemsidomide (CFT7455)
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
- IKZF1/3
- Phase 1/2
- Has results
Accepting patients
AZD0305
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- GPRC5D
- Phase 1/2
Accepting patients
WS-CART-CS1
Phase 1 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
- Phase 1
Accepting patients
Horizon Adaptive Platform
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
- BCMA
- CD3
- Randomization
- Phase 2
2 hidden based on your filters. Show All